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Abstract
Seed researchers, like anybody else working with
materials containing genes, have to deal with a variety
of rules. Their ‘freedom to operate’ does not only
depend on intellectual property rights but also on
various rights arising from biodiversity policies and
possibly traditional knowledge. The most relevant are,
however, patents on both materials and biotechnolo-
gies. It is in this field that recent developments indicate
that the pendulum of ever-increasing levels of rights
has started to swing back a little. This is due to recent
court cases both in the USA and Europe, and
emerging political debates in various countries. After
describing the general policy arena involving national
sovereign rights, private rights and ‘group-rights’ we
focus on recent trends in the patent system. Seed
scientists hardly even had to deal with such rights in
the past, but in the 21st century they need to be aware
of their implications.
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Introduction
Seed scientists work with living materials that may fall
under a variety of legal regimes at the same time. Even
though the Food and Agriculture Organisation (FAO)
International Undertaking (FAO, 1985) formally
designated genetic resources for food and agriculture
as a ‘heritage of mankind’ to be freely used by
anybody, and intellectual property rights (IPRs) did
not affect scientific work on higher plants at that time,
a number of international agreements and changes in
national application of existing laws have changed the
legal environment in which seed scientists operate
(Louwaars, 2006). Seed researchers may not always be
aware of these regulatory issues. Therefore, this paper
provides an overview of developments at the inter-
national level, with specific emphasis on the trends in
patenting plants and their components.
Biodiversity policies
Plant genetic resources became part of a binding
international agreement in 1992. The Convention on
Biological Diversity (CBD) brought all genetic
resources, including those used in agriculture, under
the sovereignty of nations (www.biodiv.org). This
means that countries can make access to such materials
subject to mutually agreed terms and prior informed
consent. In practice this means that most genetic
resources, collected after the coming into force of
the CBD in 1993 are bound to a material transfer
agreement that may specify limitations to their use in
research and/or product development. Countries may
impose widely different conditions of access to their
genetic resources. This could restrict availability of
genetic resources for research, and put the commer-
cialization of products arising from such research
subject to conditions, notably the equitable sharing of
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benefits with the provider, i.e. the country and its local
and indigenous communities. This ‘Access and
Benefit Sharing’ (ABS) was a key element in the latest
Conference of Parties of the CBD (Convention on
Biological Diversity, 2010). The Nagoya Protocol,
which was concluded in 2010, provides the basis of
internationally applicable rules for ABS that could
facilitate both access and benefit sharing.
Particularly to serve the needs of the agricultural
sector, the FAO through its Commission on Genetic
Resources for Food and Agriculture identified
limitations in the implementation of the CBD with
respect to agricultural use of genetic resources. The
key element appeared that the large number of
exchanges world-wide of these specific genetic
resources created problems with the mechanism of
bilateral negotiation for access. Furthermore, the
position of the international genebanks had to be
clarified, as were the other supporting components
that had already been developed, such as the Global
Plan of Action (1995) (www.globalplanofaction.org).
The ‘International Treaty on Plant Genetic Resources
for Food and Agriculture’ came into force in 2004.
An important component is the multilateral system
which facilitates access to genetic resources of major
food and fodder crops and arranges for multilateral
benefit sharing. These materials are shared using
a standard material transfer agreement, which spe-
cifies, among other things, that users may not take out
patents on the materials ‘in the form received’. Also,
the Treaty specified some content on the concept
of Farmers’ Rights, which member countries have to
implement at the national level (FAO, 2001).
A third process which may become very relevant
concerns the negotiations in the Intergovern-
mental Commission on Genetic Resources, Traditional
Knowledge and Folklore, (IGC) which focuses on
the (traditional) knowledge component of genetic
resources (www.wipo.int/tk/en/igc). This committee
has not created an international legal instrument
yet, but some countries have already introduced
national legislation with regard to traditional know-
ledge which may affect access to plant materials.
Relevance for seed scientists
For seed scientists it is important to know that these
agreements and the national laws derived from them
may all create legal restrictions on the use of plant
materials, and that seeds that are included in research
may have come with contracts attached to them. Seed
scientists need to verify the origin of the seeds that
they use. Particularly, those using seeds with
particular natural traits, or seeds of under-researched
plant species, may need to know whether there are
any strings attached to the use of the seed. In cases of
seeds obtained from the wild, or from a particular
community, it is important to obtain approval based
on prior informed consent from the national
competent authorities and – depending on national
law – from the communities/land owner/local
authorities in the area from which the seed, and
possibly associated traditional knowledge, originates.
This is particularly important for seed ecologists
studying the dispersal of the natural flora and coping
mechanisms based on seed physiology or mor-
phology of species.
If seed is obtained from a person who got them
from such primary sources it is also important to find
out whether approval has been obtained and which
conditions have been set, i.e. whether agreements
have been concluded that affect the use of such seed.
Failure to do so may have at least diplomatic and
sometimes legal repercussions. If seed has been
obtained legally, it is essential that the conditions of
the material transfer agreement are respected. These
may range from an obligation to recognize the origin
in publications to requirements for scientific co-
operation or technology transfer, or other sharing of
(non-) monetary benefits.
Intellectual property rights
Until the mid-1980 s, plants had not been subjected
to patent protection. The agricultural community had
developed its own system for the protection of
plant breeding. Plant breeder’s rights – later dubbed
Plant Variety Protection – do not restrict the use of
seed in research. The rise of biotechnology, however,
introduced patent rights into plant research, first
through court decisions in the United States of
America (Box 1) and much later through the adop-
tion of the Biotechnology Directive of the European
Commission (Directive 98/44/EC of the European
Parliament and of the Council of 6 July 1998 on
the legal protection of biotechnological inventions,
PB.L., no. 213, 30 July 1998, p. 13), making both
biotechnological processes and products subject to
patent protection.
At the global level, the Agreement on Trade Related
Aspects of Intellectual Property Rights (TRIPS) of the
World Trade Organisation has had a tremendous
effect on the protection levels of intellectual property
rights at the global level. For example, India had to
provide patents on products, whereas before the
TRIPS-based changes of the national patent law only
processes could be protected. However, TRIPS
includes an important exemption relevant to plant
scientists in its Article 27(3)b. Countries may exclude
plants and animals from patentability (but then
have to provide for a protection of plant varieties),
which is interpreted, for example in several African
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countries, as an exclusion of parts of plants such as
traits and genes as well. Also, Brazil, an important
agricultural country, has resisted the patenting of
genes (Octaviani, 2010).
However, in major jurisdictions, a wide range of
technologies and biotechnology products can be
patented. Initially, patents were restricted to sequen-
cing and the resulting expressed sequence tags
(ESTs), and, on the other hand, transgenics, with
protection of transformation and regeneration proto-
cols, promoters and functional genes involved in
genetically modified crops. However, the number
of patents has increased significantly over the past
decade with the creation of new applications of
molecular biology in the plant sciences, such as
marker systems, molecular mutagenesis, reverse
breeding and cis-genesis. These technologies also
yield the identification of many (single and multiple)
genes and their functions that – even though they
concern naturally occurring genes – may be patented.
In Europe this followed a decision on appeal number
G1/98 by the Enlarged Board of Appeal on patent
no. EP 0448511 B1of Novartis, which specified that
despite the fact that plant varieties cannot be patent
protected, patents can be obtained on traits that are
not confined to one variety.
The biotechnology sector provides excellent oppor-
tunities for strategic use of the patent system
(Louwaars et al., 2009). Wide claims are particularly
common in the early days of a technology. Therefore
a claim on all genetically transformed cotton based
on the first transformation technology was initially
honoured (and later withdrawn). Furthermore, reach-
through claims can be commercially very interesting,
i.e. a technological invention, claiming all materials
created with that technology plus all the offspring
created therefrom – and potentially the products
harvested and produced from such plants. Finally,
blocking patents can be useful to prevent competitors
enter a particular research domain. Such uses of the
patent system carry the risk of developing patent
thickets (Bobrow and Thomas, 2000; Reitzig, 2004),
leading to restrictions for further research and thus
contributing to a tragedy of the anticommons
(Heller and Eisenberg, 1998). Even though patent
thickets may not be impenetrable for those who have
the legal and technical capacity to study patent
landscapes in detail, for smaller companies and
universities the existence of a multitude of patents in
any particular research area is likely to deter them
from pursuing their research (Louwaars et al., 2009).
Recent trend: increasing debate on the roles
of patents
The patenting of plants is the lifeline of important sub-
sectors within the global seed world, notably the maize
seed business. Other breeders and seed companies
have to determine whether they could play the game
or whether they should oppose it. Plantum.NL, the
Dutch seed association, has taken an explicit position
in this debate by stating that the patent system is
stifling innovation and should be changed by
exhausting the patent rights on plant biotechnological
inventions at the level of the use of materials in
practical variety development (Plantum, 2009). They
call for a ‘breeder’s exemption’ as in plant breeder’s
rights, including materials that fall within the claim of
a patent. This would make all modern varieties
available for further breeding by all breeders, which
has been the practice in the plant breeding sector
under the concept that plant breeding is a cumulative
enterprise – that all breeders stand on the shoulders
of their predecessors, including the generations of
farmers who developed the crops from their weedy
ancestors. Unlike common-law countries, such a
change in Europe calls for an amendment of patent
law. The position was based on a majority vote of
the membership of the Dutch seed association with –
initially – only the few large multinational company
members of Plantum.NL opposing. In response to this
position the Dutch ministries of agriculture and the
economy called for a study on ‘the future of plant
breeding in the light of developments in patent rights
and plant breeder’s rights’ (Louwaars et al., 2009).
Box 1. Landmark decisions on patents in the USA.
. Diamond v. Chakrabarty 447 US 303, 206 USPQ 193 (1980), which involved the first patent on a man-
made micro-organism.
. Plants were considered patentable following the ruling in ex-parte Hibberd, 227 U.S.P.Q. 443 (Bd. Pat.
App. 1985).
. In J.E.M. AG Supply Inc. v. Pioneer HiBred International, Inc. 534 US 124, the US Supreme Court held that
utility patents may be issued for plant varieties and plant seeds, and that rights under either the Plant
Patent Act of 1930 or the Plant Variety Protection Act of 1970 would not reduce the patentability.
Source: Louwaars et al. (2009)
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Based on literature research and interviews, the study
identified that the concentration in the global seed
sector (Le Buanec, 2007) is triggered by three major
causes: cost of new technologies, general globalization
of trade and patents. It concluded that if
. breeding is to continue to be a main tool towards
food security and sustainable agriculture;
. access to genetic resources is considered import-
ant;
. innovation strength of the sector is to be pre-
served/increased;
. diversity of companies is key for healthy compe-
tition;
. the Dutch breeding sector is to safeguard its
position;
. a decent profit margin is to be made possible; and
. IPRs are considered to be one of the keys;
then the following three actions should be considered
to improve the patent system:
(1) The industry itself could – through a code of
conduct – reduce strategic uses of the patent
system that are considered most detrimental to
downstream innovation at the level of plant
breeding.
(2) The patent offices should play an important role
in increasing patent quality, thus reducing the
number of plant science patents, improving
the clarity of the boundaries of claims and of the
enabling publication of the invention.
(3) Change of patent law to include a breeder’s
exemption. This could be done at three levels:
(i) allow the use of plant materials falling within a
patent claim for further breeding, but when
a patented component (trait or other construct)
is present – and functional – in the new variety,
then consent needs to be sought from the patent
holder;
(ii) a full breeder’s exemption, meaning that any
material can be used for further breeding and the
new variety may be freely marketed by the
breeder; and
(iii) exempt plants and their components from patent
protection.
Finally, the study stressed taking the following policy
fields into account:
. competition law, which deals with the other side
of the monopolies created by IPRs;
. development policy, basically stressing that
if the Netherlands wants to balance the rights
of the inventor with those of society, developing
countries should not be forced in bilateral trade
negotiations to strengthen their IPRs beyond their
immediate needs;
. public research policies, making sure that such
research contributes to public values (De Jonge
and Louwaars, 2009) and does not unnecessarily
contribute to patent thickets, and that research
areas that the private sector may leave, because
of lack of incentives, will be covered.
The debate in parliament led to a request to the
seed association Plantum.NL to develop two working
groups, consisting of different types of companies, to
identify opportunities to develop a solution to strategic
patenting. Ideas were developed to create patent pools
and to exempt natural genes from patentability.
The groups have not yet concluded their deliberations.
The government furthermore confirmed that
patents and plant breeder’s rights seem out of
balance, that access to genetic resources needs to be
supported, and that the ministers will raise the
issue in their respective tasks in the European
Commission. Further, that support to the ‘raising the
bar’ process at the European Patent Office (EPO)
would need to be given. By the time of the report the
EPO had already presented an initiative to do this
under the title ‘raising the bar’. However, patent
offices need to take into account that raising the bar too
much could invite large numbers of court cases. In
addition, the International Seed Federation started a
programme to educate patent examiners at the United
States Patent and Trademark Office (USPTO) and EPO
in methods of plant breeding, with the aim to better
identify innovativeness (non-obviousness) of claims
involving selection methods.
Finally, the ministers promised further research
to identify the legal consequences of the options to
change patent law. That analysis concluded that
the first option (restricted breeder’s exemption) is
possible since other European countries had already
introduced such clauses in their national patent laws;
that the full breeder’s exemption, which makes some
types of patents virtually worthless, may create a
conflict with Article 30 of TRIPS which states:
‘Members may provide limited exceptions to the
exclusive rights conferred by a patent, provided that
such exceptions do not unreasonably conflict with
a normal exploitation of the patent and do not
unreasonably prejudice the legitimate interests of
the patent owner, taking account of the legitimate
interests of third parties.’ Finally, exempting plants
from patent protection is explicitly compatible with
TRIPS but conflicts with the Biotechnology Direc-
tive of the European Union. Furthermore, such a
solution to the problem in the plant breeding sector
would also have severe repercussions to other
technology sectors that use plants, such as pharma-
ceutical and industrial biotechnology.
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Has the pendulum started to swing back?
Since the decision in the Chakrabarty case in the
USA in 1980 (see Box 1), more and more outcomes of
plant biotechnological research have been protected
by patents, the vast majority of which are held
by very few companies (Louwaars et al., 2009). The
pendulum has been swinging in that upward direction
until recently.
The debate in society is much broader than the
discussion triggered by Plantum.NL and is contribut-
ing to a number of decisions that has an increasing
impact on the patenting of life. These court decisions,
in both the USA and Europe, are attacking patent
claims from all possible sides. First the utility
(industrial application) requirement was put to
the test when patents on ESTs were abolished
following in re Fisher 421 F.3d 1365 (Federal Circuit,
2005). In April, 2009 a potentially far-reaching
conclusion was reached by the United State Court
of Appeals for the Federal Circuit in re Marek
Z. Kubin and Raymond G. Goodwin (http://www.
cafc.uscourts.gov/opinions/08-1184.pdf) which con-
sidered a patent for a gene that codes for an already
known protein not unobvious (not inventive). This
could impact a particular class of gene patents. Finally,
the District Court of New York arrived at a very
far-reaching verdict in the opposition by the Associ-
ation for Molecular Pathology against a patent
granted by the United States Patent and Trademark
Office (Case 1:09 cv-04 515-RWS; http://www.aclu.
org/files/assets/2010-3-29-AMPvUSPTO-Opinion.
pdf) involving a human gene coding for suscep-
tibility to breast cancer. If this reasoning holds in the
higher courts, this would likely nullify all claims on
naturally occurring genes.
In Europe, two recent cases (December 2010) con-
tributed further to the expectation that the pendulum
may be swinging back. In a case on Argentine soybean
meal originating from herbicide-tolerant (Roundup-
Ready) soybean on which Monsanto claimed rights
in Europe, the patent owner lost because, even
though the patented gene may be present in the
ground soy, the gene was considered not functional
in that state and thus the patent rights exhausted. The
full consequences of this decision by the Grand
Chamber of the European Court of Justice (case
C/428-08; C:2010:234:0007:0008:EN:PDF">http://
eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri ¼
OJ:C:2010:234:0007:0008:EN:PDF) – for example on
health claims based on genes – are not clear yet,
but it showed a critical attitude to the rights of
patent holders. The swing was further confirmed by
a decision of the Enlarged Board of Appeal of the
European Patent Office in December 2010 (G 2/07 and
G 1/08 for broccoli and tomato, respectively; http://
www.epo.org/news-issues/news/2010/20101209a.
html), turning down patent claims on natural genes
and breeding methods to transfer such traits in plants.
It is likely that the courts on both sides of the Atlantic
are sensitive to the public debate regarding the
patenting of life forms, which shows – similar to
the upswing of the pendulum in the 1980 s – that the
courts are indeed part of society.
Relevance of IPRs for seed technologists
IPRs may create opportunities for seed technologists to
develop spin-off companies from university research,
or commercial markets for inventions such as seed
treatment methods. Patents, however, may also create
restrictions to the use of both materials and technol-
ogies in research. It is important to know the scope of
the research exemption in your country (Ludwig
and Chumney, 2003; Waltz, 2009), and identify which
types of risks the use of patented technologies carry.
These may vary in the research phase and in the
creation of commercial products out of such research.
If research is aimed at producing practical uses, it may
be useful to do a Freedom-to-Operate analysis before
using seeds that may carry patented traits or that may
be included in other patent claims. This is important
because, if something useful comes out of the research,
the patent holder may be allowed to claim exclusive
rights on such uses.
Conclusion
Even though rights on the materials and the
technologies that seed scientists use may not be at
the forefront of the scientist’s mind, they may require
some serious considerations in ‘seed science in the
21st century’. There are some trends for both
biodiversity rights and intellectual property rights to
become a little bit more manageable, but both types of
rights can significantly affect the freedom to operate in
both research and product development based on seed
science and technology.
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